Information about a discontinued drug
In their research letter on the extent to which publication in the biomedical literature concerning drug-induced harm can influence the legal process, David Juurlink and colleagues mention that the manufacturer of gatifloxacin stopped marketing the drug worldwide on May 1, 2006.
1 Health Canada issued a number of alerts about the potential for this product to interfere with glucose metabolism 2,3 but never bothered to formally inform either the public or health care professionals that oral and intravenous forms of this drug were withdrawn from sale in Canada. The only place where one can find this information is by searching the discontinued products in Health Canada's Drug Product Database (http: //cpe0013211b4c6d-cm0014e88ee7a4 .cpe.net.cable.rogers.com/dpdonline /searchRequest.do). This failure to communicate important information about a drug raises serious concerns about Health Canada's ability to keep health care professionals and the public informed about safety issues. When the 2004 Canadian Community Health Survey was conducted it was the first time that an internationally validated instrument was used to measure the epidemiology of food insecurity in the Canadian population. 3 The survey found that 9.2% of households (1.1 million) experienced income-related household food insecurity. Children are regularly spared food deprivation in food-insecure households 2,4 and this was reflected in the fact that 5.2% of children experienced food insecurity whereas 9.0% of adults did. 3 The percentage of children who actually experience hunger is small: 1-2% 5 or 0.4%. 3 In contrast, 2.9% of adults in the Canadian Community Health Survey were severely food insecure or hungry. Between one-fifth and one-third of people reporting food insecurity seek assistance from a food bank. 5, 6 Lone mothers are most likely to seek such assistance, 5 which probably accounts for the high percentage of children who are deemed to be recipients of food from food banks.
1 Although absolutely no child in Canada should experience hunger, food insecurity in Canada is not synonymous with food bank counts.
We support Kennedy's recommendations to address food insecurity in Canada and his call for physicians to advocate for social justice measures that eliminate the abject poverty that results in severe food insecurity. However, a discussion of hunger that focuses on the needs of children while ignoring the needs of adults and that defines child hunger solely on the basis of the counts of children who are food bank users does not reflect the true number or make-up of Canadians who are food insecure and can unintentionally perpetuate the myth of parental neglect of poor children.
Krever: the recommendation not followed I read with interest Kumanan Wilson's commentary on the contributions of the report of the Krever Commission to public health in Canada.
1 Of Justice Krever's 50 recommendations, it was the first (no-fault compensation for people who experienced injuries
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2 He considered that recommendation to be part and parcel of the precautionary principle because it would have served to balance the pressures of extreme risk aversion (by regulatory bodies and health care agencies, among others) with the need to move ahead with new treatments or to respond to unanticipated challenges. It put the dignity of patients first. Regrettably, it has not been adopted.
Krever recognized that blood is not another drug but rather a complex biological product that can never be completely characterized. Given this fact, his first recommendation was remarkably prescient. As we enter the world of targeted biopharmaceuticals, more and more of our therapies begin to look like blood products in their subtle complexity. My guess is that we are going to have to revisit the issue of no-fault compensation as part of a complete reframing of our drug development process, lest we stifle innovation or drive the costs of new drugs to unaffordable levels.
Harvey Schipper BASc(Eng) MD
Founding Member of the Board of Directors, Canadian Blood Services, Toronto, Ont.
Colorectal cancer screening
In their editorial on screening for colorectal cancer, Alan Barkun and Ken Flegel exaggerated the screening rate for this disease in the United States.
1 They cited a survey in which adults over 50 years of age were asked if they had ever undergone fecal occult blood testing, sigmoidoscopy or colonoscopy.
2 Sixtythree percent of the respondents replied that they had; Barkun and Flegel cited this figure as evidence of greater uptake of screening in the United States. However, only 37% of the respondents in that study were defined as being "current for testing" (that is, they claimed to have undergone fecal occult blood testing in the past year, sigmoidoscopy in the past 5 years or colonoscopy in the last 10 years). This survey was subject to recall bias in 2 ways: some respondents might have wanted to show that they were aware of current screening recommendations (and thus they would have responded falsely that they had been screened) and some might have responded that they had been screened when in fact they had undergone these tests for investigation rather than screening purposes.
David Lieberman has estimated the rate of colorectal cancer screening in primary care in the United States to be between 26% and 32%.
3 This rate is not much different from the rate in Canada and is not corrected to take into account patients without access to primary care. 
